Viatris And Biocon’s US Bevacizumab Hit By Indefinite Delay
Potential Third Avastin Biosimilar Hit By COVID-19 Inspection Uncertainty
Viatris and partner Biocon have seen FDA action on their application for a bevacizumab biosimilar rival to Avastin delayed by the need for a facility inspection, the timing of which is uncertain due to coronavirus-related restrictions.
